Flyer

Archives in Cancer Research

  • ISSN: 2254-6081
  • Journal h-index: 14
  • Journal CiteScore: 3.77
  • Journal Impact Factor: 4.09
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • OCLC- WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • J-Gate
  • Secret Search Engine Labs
  • International Committee of Medical Journal Editors (ICMJE)
  • Zenodo
Share This Page

Development of reproducible and versatile recombinant antibodies for epigenetics research

International Conference on Cancer Epigenetics and Biomarkers
October 26-28, 2017 Osaka, Japan

Masato Yonezawa, Bryce Alves, Romila Mukerjea, Laura Carpenter, Leo Lingchun Kong, Fei Lan and Terry Kelly

Active Motif Inc., USA Active Motif China, China

Posters & Accepted Abstracts: Arch Can Res

Abstract:

Epigenetics research significantly relies on antibody-dependent experiments and researchers can ruin a significant amount of budget and time due to insufficient quality and reproducibility of antibodies. To ensure future sustainability and minimal lot-to-lot variation, we applied a recombinant antibody approach to convert mouse and rabbit monoclonal antibodies into a synthetic framework, allowing facile cloning of CDR diversity regions into a standard mouse or rabbit IgG backbone and expressed them in HEK293 cells. We also introduced flexible functional tags including the Sortase tag on the C-terminus of the heavy chains to allow uniform, enzymatic conjugation to various materials in combination with a hyperactive pentamutant sotrase (Sortase A5). We present demonstration of conjugation for fluorescent applications, Western blotting, ChIP and ELISA applications. We observed that recombinant antibodies give dramatically improved reactivity and specificity in ELISA assays. We also proposed extended applications of these recombinant antibodies.

Biography :

Masato Yonezawa has nearly 20 years of experience in epigenetics research in academia and industries. He has completed his PhD from Waseda University, Tokyo, Japan and worked as a Postdoctoral Fellow at Research Institute of Molecular Pathology (IMP), Vienna, Austria. He is currently working at Active Motif Inc. CA, USA.